Alpha 2.0
Login Register
» Authors » Peter Trask

Peter Trask

Explore the profile of Peter Trask including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 417
Followers 0
Related Specialties
Hematology
Oncology
Public Health
Top 10 Co-Authors
Sylvia von Mackensen
Johannes Oldenburg
Michaela Lehle
Elina Asikanius
Midori Shima
Rebecca Kruse-Jarres
Johnny Mahlangu
Michael U Callaghan
Sammy Chebon
Chiun-Sheng Huang
Published In
Haemophilia
J Clin Oncol
Fam Med
Nicotine Tob Res
Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Subbiah V, Hu M, Mansfield A, Taylor M, Schuler M, Zhu V, et al.
Thyroid . 2023 Nov; 34(1):26-40. PMID: 38009200
Rearranged during transfection () alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a...
2.
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials
King-Kallimanis B, Calvert M, Cella D, Cocks K, Coens C, Fairclough D, et al.
Value Health . 2023 Jul; 26(10):1543-1548. PMID: 37422075
Objectives: Patient-reported outcome (PRO) data are critical in understanding treatments from the patient perspective in cancer clinical trials. The potential benefits and methodological approaches to the collection of PRO data...
3.
Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis
Canales M, Buchholz T, Bortolini J, Fogliatto L, Ishikawa T, Izutsu K, et al.
Hemasphere . 2023 Apr; 7(4):e860. PMID: 37008164
No abstract available.
4.
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3
Callaghan M, Asikanius E, Lehle M, Oldenburg J, Mahlangu J, Uguen M, et al.
Res Pract Thromb Haemost . 2022 Sep; 6(6):e12782. PMID: 36171959
Background: Bleeding in people with hemophilia A can be life threatening, and intra-articular bleeds can result in joint damage. Most clinical studies focus on treated bleeds, while bleeds not treated...
5.
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
Krop I, Im S, Barrios C, Bonnefoi H, Gralow J, Toi M, et al.
J Clin Oncol . 2021 Dec; 40(5):438-448. PMID: 34890214
Purpose: We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab...
6.
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
OShaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, et al.
Eur J Cancer . 2021 Jun; 152:223-232. PMID: 34147014
Aim: The aim of the study was to assess patient preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in patients with HER2-positive early...
7.
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study
Stilgenbauer S, Bosch F, Ilhan O, Kisro J, Mahe B, Mikuskova E, et al.
Br J Haematol . 2021 Feb; 193(2):325-338. PMID: 33605445
The manageable toxicity profile of obinutuzumab (GA101; G) alone or with chemotherapy in first-line (1L; fit and non-fit) and relapsed/refractory (R/R) patients with chronic lymphocytic leukaemia (CLL) was established in...
8.
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study
Oldenburg J, Tran H, Peyvandi F, Nunez R, Trask P, Chebon S, et al.
Haemophilia . 2021 Feb; 27(3):398-407. PMID: 33576546
Introduction: Real-world data on health-related outcomes in persons with haemophilia A (PwHA) can provide useful information for improving patient care. The global, non-interventional study (NIS; NCT02476942) prospectively collected high-quality data...
9.
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
Kempton C, Trask P, Parnes A, Niggli M, Campinha-Bacote A, Callaghan M, et al.
Haemophilia . 2021 Jan; 27(2):221-228. PMID: 33506955
Introduction: Emicizumab is a subcutaneously (SC) administered prophylactic agent for persons with haemophilia A (PwHA). As part of its clinical development, a new instrument was required to measure treatment satisfaction....
10.
Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study
Mancuso M, Mahlangu J, Sidonio Jr R, Trask P, Uguen M, Chang T, et al.
Haemophilia . 2020 Oct; 26(6):1009-1018. PMID: 33084175
Introduction: Persons with haemophilia A (PwHA) with factor (F)VIII inhibitors, including children, have impaired health-related quality of life (HRQoL). The HAVEN 2 study (NCT027955767) of paediatric PwHA with FVIII inhibitors...